| Literature DB >> 26029826 |
S Ghafoory1, A Mehrabi2, M Hafezi2, X Cheng1, K Breitkopf-Heinlein3, M Hick1, M Huichalaf1, V Herbel1, A Saffari2, S Wölfl1.
Abstract
Expression of E-cadherin has a central role in maintaining epithelial morphology. In solid tumors, reduction of E-cadherin results in disruption of intercellular contacts. Consequently, cells lose adhesive properties and gain more invasive mesenchymal properties. Nevertheless, the mechanism of E-cadherin regulation is not completely elucidated. Here we analyzed the distribution of E-cadherin expression at the cell level in human hepatocellular carcinoma, in which human liver paraffin blocks from 25 hepatocellular carcinoma patients were prepared from cancerous (CA) and noncancerous areas (NCA). In situ hybridization (ISH) was performed to detect E-cadherin and hypoxia-induced factor-1α (HIF1α) mRNAs and immunohistochemistry to stain E-cadherin protein. In parallel, RNA was extracted from CA and NCA, and E-cadherin and HIF1α were quantified by quantitative reverse transcription PCR. ISH revealed abundant E-cadherin mRNA in nuclei of hepatocellular carcinoma cells (HCCs), whereas immunohistochemistry showed depletion of E-cadherin protein from these areas. In sections of NCA, E-cadherin mRNA was also found in the cytosol, and E-cadherin protein was detected on the membrane of cells. Experiments in cell lines confirmed E-cadherin mRNA in nuclei of cells negative for E-cadherin protein. HIF1α expression is elevated in CAs, which is associated with a clear cytosolic staining for this mRNA. Our results demonstrate that E-caderhin mRNA is selectively retained in nuclei of HCCs, whereas other mRNAs are still exported, suggesting that translocation of E-cadherin mRNA from nuclei to cytoplasm has a role in regulating E-cadherin protein levels during epithelial mesenchymal transition.Entities:
Year: 2015 PMID: 26029826 PMCID: PMC4753520 DOI: 10.1038/oncsis.2015.11
Source DB: PubMed Journal: Oncogenesis ISSN: 2157-9024 Impact factor: 7.485
Figure 1E-cadherin expression in hepatocellular carcinoma tissues. (a) CDH1 mRNA staining (violet) in CAs and NCAs from two HCC patients. In CAs, CDH1 mRNA is only detected in the nucleus; in NCAs, CDH1 mRNA staining is visible in both nucleus and cytosol. (b) Hybridization (violet) for Albumin mRNA, a liver-specific gene highly expressed in hepatocytes. Albumin mRNA is detected in CAs and NCAs of the same HCC patients (as in a). The staining (violet) for albumin mRNA is stronger in the cytoplasm of both CAs and NCAs. (c) Detection of E-cadherin at the protein level using two different primary and secondary antibodies (green or red) and overlay with mRNA staining (brown) in two HCC patients. Loss of E-cadherin protein staining in membranes of cells in CAs correlates with high nuclear CDH1 mRNA levels, whereas in NCAs a clear membranous staining pattern of E-cadherin correlates with a clear cytosolic staining of CDH1 mRNA and a weaker nuclear signal. (d) Fluorescence ISH using an anti-DIG-Cy3 antibody for the detection of hybridized antisense E-cadherin probes in CAs and NCAs from one patient. Nuclei were visualized by Hoechst staining (blue). The overlay between blue (nuclei) and red (CDH1 mRNA) fluorescence corroborates CDH1 mRNA retention in nuclei in CAs, whereas in NCAs CDH1 mRNA is mostly located in the cytoplasm.
Figure 2HIF1α and E-cadherin mRNA and protein level distribution in patients tissues. (a) Comparative ISH with co-staining for HIF1α (red) and E-cadherin (violet) mRNA expression in CA and NCA sections. Already at the lower magnification an intense nuclear staining for CDH1 mRNA (violet) and a clear cytoplasmic staining for HIF1α mRNA (red) can be seen in CAs, whereas in NCA the signal for HIF1α mRNA (red) is lower but still in the cytoplasm and also the signal for CDH1 mRNA (violet) is lower in nuclei. (b) Detection of E-cadherin and HIF1α at the protein level by FIHC in NCA and CAs. Athought E-cadherin protein is highly expressed and visible in cell membranes in NCA, HIF1α protein is highly abundant in the cytoplasm in CAs.
Figure 3Quantification of CDH1 and HIF1α mRNA and mRNA distribution. (a and b) Overall levels of CDH1 (a) and HIF1α (b) mRNA quantified by RT–qPCR from total RNA isolated from CA and NCA tissue sections of 12 patients. The ratio of CDH1 and HIF1α mRNA between CAs and NCAs was calculated as fold induction over the NCA expression levels, showing changes in both directions, increase or decrease in CA vs NCA tissue sections. beta-actin was used as reference for normalization. (c) Comparison of the CA vs NCA fold difference of CDH1 and HIF1α mRNA shown in (a) and (b) for all patient samples. Despite the wide distribution of values (ratios), a pearson correlation factor was calculated for the assumption that E-cadherin and HIF1α differences between CAs and NCAs in HCC patients would correlate.
Figure 4Expression and distribution of E-cadherin in cancer cell lines. (a) Staining of CDH1 at mRNA (violet) and protein (red) levels in HLE and MCF7 cell lines revealed that loss of E-cadherin protein signal in HLE cells is directly correlated with a higher signal for CDH1 mRNA in the cell nucleus. In contrast, in MCF7 cells, cytoplasmic CDH1 mRNA levels are high and correlate with high E-cadherin protein levels, resulting in a clear detection of E-cadherin protein localized in cell membranes. (b) Comparison of CDH1 staining by using two different E-cadherin antisense RNA probes (Table 1) (violet) in HLE cell line. Probes were designed for the detection of different parts of CDH1 mRNA (coding and non-coding sequences). Independent of the probe used for CDH1 mRNA detection, similar nuclear and cytoplamsic staining is observed. (c) Relative distribution of mRNA from nuclear and whole-cell extracts of HLE and MCF7 cell lines analyzed for CDH1 and beta-actin mRNA by RT–qPCR. Detailed values are shown in Table 3.
Patient information
| M | 60 | HCC | 2.5 cm | HCV infection | 2 × TACE | — |
| M | 25 | HCC | 1 × 3 × 2 cm | HBV infection | — | pT2, PN0, V1, R0 |
| F | 77 | HCC | 5 × 5.7 × 6.3 cm | Cryptogenic liver cirrhosis | — | pT1, pN0, G2 |
| M | 70 | HCC | — | Alcoholic liver cirrhosis | — | — |
| M | 79 | HCC | 1.0 × 1.0 × 0.8 cm | Alcoholic liver cirrhosis | 3 × TACE | pT1, pN0, pM1, G2 |
| M | 57 | HCC | 2.2 × 1.5 × 3 cm | HBV infection | 1 × TACE | pT3, pN0, M0 |
| M | 76 | HCC | 1.4 × 1.9 cm | HBV infection | — | pT1, pN0, G1 |
| M | 82 | HCC | — | — | — | — |
| M | 38 | HCC | — | — | Nexavar | — |
| M | 68 | HCC | 5.3 × 4 × 4 and 1.2 × 1.2 cm (2 tumors) | Alcoholic liver cirrhosis | — | pT2, G3 |
| M | 53 | HCC | 3.5 | HBV, HCV (alcoholic liver cirrhosis) | — | pT2, pN0, M0, G2 |
| M | 76 | HCC | 3.6 | HBV (alcoholic liver cirrhosis) | — | pT2, N0, M0, G3 |
| F | 33 | HCC–CCC | 2.3 | Autoimmune hepatitis | Nexavar | pT1, N0 |
| M | 57 | HCC | — | HCV infection | — | — |
| M | 63 | HCC | 14 | HCV infection | — | pT3a, pN0, G2 |
| M | 63 | HCC | 2.2 | Alcoholic liver cirrhosis | — | PT1 G2 |
| F | 75 | HCC | 3 | HCV+HBV infections | — | pT2, PN0, G2 |
| M | 66 | HCC | 2.5 | Alcoholic liver cirrhosis | — | Pt2, PN0, G2 |
| M | 60 | HCC | 2.5 | HBV infection | — | pT1, G2, R0 |
| M | 69 | HCC | — | Alcoholic liver cirrhosis | 4 × TACE | rpT1, N0, G2 |
| M | 68 | HCC | 3.2 | — | — | pT1, pN0, G2 |
| M | 77 | HCC | 0.5 | — | — | — |
| F | 71 | HCC | 2.7 | Steatohepatitis | — | PT3b, G2 |
| F | 77 | HCC | 3.7 | Steatohepatitis | — | PT1, PN0, G2 |
| M | 77 | HCC | 5 | Hemochromatose | — | PT2, PN0, G2 |
Abbreviations: CCC, cholangiocellular carcinoma; F, female; HBV, hepatitis b virus; HCV, hepatitis c virus; HCC, hepatocellular carcinoma cell; M, male.
Primer sequences and the length of each antisense or qRT–PCR products
| E-cadherin | NM_004360.3 | ISH | 910 | 5′-CCCGCCTTATGATTCTCTGCTCGTG-3′ | 5′-CTGTAATCCCAATACTCTGGGAGGC-3′ |
| 884 | 5′-GTGACAGAGCCTCTGGATAGAGAAC-3′ | 5′-GCAGTGTAGGATGTGATTTCCTGGC-3′ | |||
| qRT–PCR | 160 | 5′-CCCGCCTTATGATTCTCTGCTCGTG-3′ | 5′-TCCGTACATGTCAGCCAGCTTCTTG-3′ | ||
| HIF1α | NM_001243084.1 | ISH | 837 | 5′-CATGGAAGGTATTGCACTGCACAGG-3′ | 5′-CAGCACTACTTCGAAGTGGCTTTGG-3′ |
| qRT–PCR | 189 | 5′-CATGGAAGGTATTGCACTGCACAGG-3′ | 5′-TCATATCCAGGCTGTGTCGACTGAG-3′ | ||
| ACTB | NM_001101 | qRT–PCR | 201 | 5′-CTGACTACCTCATGAAGATCCTC-3′ | 5′-CATTGCCAATGGTGATGACCTG-3′ |
| Albumin | NM_000477 | ISH | 1403 | 5′-GGTGAGACCAGAGGTTGATGTGATG-3′ | 5′-CACACATAACTGGTTCAGGACCACG-3′ |
Abbreviations: HIF1α, hypoxia-induced factor-1α ISH, in situ hybridization; qRT–PCR, quantitative reverse transcription–PCR.
E-cadherin antisense RNA1.
E-cadherin antisense RNA2.
E-cadherin and beta-actin Ct values for different RNA sources
| HLE nucleus | 26.8 | 19.3 |
| HLE whole-cell lysate | 25 | 16.53 |
| MCF7 nucleus | 19.6 | 18.33 |
| MCF7 whole-cell lysate | 17.44 | 13.95 |
Abbreviation: Ct, threshold cycle.